Rectum Adenocarcinoma: Mutation Analysis (MutSig v1.5)
(primary solid tumor cohort)
Maintained by Dan DiCara (Broad Institute)
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v1.5 was used to generate the results found in this report.

- Working with individual set: READ-TP

- Number of patients in set: 69

Input

The input for this pipeline is a set of individuals with the following files associated for each:

1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

2. A .wig file that contains information about the coverage of the sample.

Summary

- MAF used for this analysis:READ-TP.final_analysis_set.maf

- Significantly mutated genes (q ≤ 0.1): 26

- Mutations seen in COSMIC: 222

- Significantly mutated genes in COSMIC territory: 10

- Genes with clustered mutations (≤ 3 aa apart): 117

- Significantly mutated genesets: 111

- Significantly mutated genesets: (excluding sig. mutated genes):0

Mutation Preprocessing

- Read 38 MAFs of type "Broad"

- Read 35 MAFs of type "Baylor-SOLiD"

- Total number of mutations in input MAFs: 29413

- After removing 257 invalidated mutations: 29156

- After removing 200 noncoding mutations: 28956

- After collapsing adjacent/redundant mutations: 21679

Mutation Filtering

- Number of mutations before filtering: 21679

- After removing 200 mutations outside gene set: 21479

- After removing 172 mutations outside category set: 21307

- After removing 2 "impossible" mutations in

- gene-patient-category bins of zero coverage: 20933

Results
Breakdown of Mutations by Type

Table 1. Get Full Table Table representing breakdown of mutations by type.

type | count
--- | ---
De_novo_Start_InFrame | 4
De_novo_Start_OutOfFrame | 30
Frame_Shift_Del | 151
Frame_Shift_Ins | 155
In_Frame_Del | 27
In_Frame_Ins | 7
Missense_Mutation | 14471
Nonsense_Mutation | 1779
Nonstop_Mutation | 6
Read-through | 10
Silent | 4629
Splice_Site | 38
Total | 21307

Breakdown of Mutation Rates by Category Type

Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category | n | N | rate | rate_per_mb | relative_rate
--- | --- | --- | --- | --- | ---
*CpG->T | 4919 | 99673101 | 0.000049 | 49 | 5.4
*Cp(A/C/T)->mut | 6673 | 832257993 | 8e-06 | 8 | 0.89
A->mut | 2743 | 908854391 | 3e-06 | 3 | 0.33
*CpG->(G/A) | 135 | 99673101 | 1.4e-06 | 1.4 | 0.15
indel+null | 2050 | 1840785523 | 1.1e-06 | 1.1 | 0.12
double_null | 157 | 1840785523 | 8.5e-08 | 0.085 | 0.0094
Total | 16677 | 1840785523 | 9.1e-06 | 9.1 | 1

Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).

Figure 1.

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2. Patients counts and rates file used to generate this plot: READ-TP.patients.counts_and_rates.txt

CoMut Plot

Figure 3. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

- N = number of sequenced bases in this gene across the individual set

- n = number of (nonsilent) mutations in this gene across the individual set

- npat = number of patients (individuals) with at least one nonsilent mutation

- nsite = number of unique sites having a non-silent mutation

- nsil = number of silent mutations in this gene across the individual set

- n1 = number of nonsilent mutations of type: *CpG->T

- n2 = number of nonsilent mutations of type: *Cp(A/C/T)->mut

- n3 = number of nonsilent mutations of type: A->mut

- n4 = number of nonsilent mutations of type: *CpG->(G/A)

- n5 = number of nonsilent mutations of type: indel+null

- n6 = number of nonsilent mutations of type: double_null

- p = p-value (overall)

- q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 26. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | TP53 | tumor protein p53 | 79667 | 45 | 45 | 30 | 1 | 19 | 6 | 6 | 2 | 12 | 0 | 1.2e-15 | 2.2e-11
2 | APC | adenomatous polyposis coli | 576224 | 66 | 57 | 56 | 0 | 1 | 4 | 4 | 0 | 39 | 18 | 3.9e-15 | 3.5e-11
3 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 48604 | 38 | 38 | 8 | 0 | 0 | 36 | 1 | 0 | 1 | 0 | 6e-15 | 3.6e-11
4 | SMAD4 | SMAD family member 4 | 115264 | 8 | 8 | 6 | 0 | 2 | 3 | 3 | 0 | 0 | 0 | 8.1e-11 | 3.6e-07
5 | KIAA1804 |  | 162266 | 11 | 9 | 9 | 0 | 7 | 3 | 1 | 0 | 0 | 0 | 1.2e-08 | 0.000045
6 | FBXW7 | F-box and WD repeat domain containing 7 | 177744 | 12 | 9 | 10 | 0 | 6 | 2 | 2 | 0 | 2 | 0 | 2e-08 | 0.000058
7 | TCF7L2 | transcription factor 7-like 2 (T-cell specific, HMG-box) | 119026 | 7 | 7 | 7 | 1 | 2 | 3 | 0 | 0 | 2 | 0 | 1e-07 | 0.00024
8 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 40433 | 5 | 5 | 4 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 1.1e-07 | 0.00024
9 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 194975 | 7 | 7 | 7 | 1 | 1 | 3 | 3 | 0 | 0 | 0 | 2.1e-07 | 0.00042
10 | OPCML | opioid binding protein/cell adhesion molecule-like | 73709 | 6 | 6 | 6 | 1 | 1 | 3 | 0 | 0 | 2 | 0 | 2.8e-07 | 0.00051
11 | SPATA8 | spermatogenesis associated 8 | 20140 | 3 | 3 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 4.2e-06 | 0.0068
12 | KRTAP5-5 | keratin associated protein 5-5 | 34487 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0.000021 | 0.028
13 | SMAD2 | SMAD family member 2 | 98964 | 5 | 5 | 5 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 0.000022 | 0.028
14 | IL1RAPL2 | interleukin 1 receptor accessory protein-like 2 | 139823 | 5 | 5 | 4 | 2 | 2 | 1 | 0 | 0 | 2 | 0 | 0.000022 | 0.028
15 | CSMD1 | CUB and Sushi multiple domains 1 | 392008 | 12 | 9 | 12 | 2 | 4 | 4 | 2 | 0 | 1 | 1 | 0.000024 | 0.029
16 | LRRTM2 | leucine rich repeat transmembrane neuronal 2 | 59242 | 5 | 4 | 5 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0.000035 | 0.04
17 | SGCB | sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) | 64145 | 4 | 4 | 4 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0.000046 | 0.046
18 | GFRA1 | GDNF family receptor alpha 1 | 86296 | 5 | 5 | 5 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 0.000046 | 0.046
19 | CCBP2 | chemokine binding protein 2 | 79700 | 5 | 5 | 5 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 5e-05 | 0.047
20 | LPHN3 | latrophilin 3 | 147364 | 7 | 6 | 7 | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 0.000059 | 0.049
21 | ZIM3 | zinc finger, imprinted 3 | 98103 | 6 | 5 | 6 | 0 | 1 | 1 | 3 | 0 | 1 | 0 | 6e-05 | 0.049
22 | MAP2K3 | mitogen-activated protein kinase kinase 3 | 67262 | 4 | 4 | 4 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 6e-05 | 0.049
23 | FAM123B | family with sequence similarity 123B | 190503 | 8 | 6 | 8 | 1 | 0 | 2 | 1 | 0 | 5 | 0 | 0.000081 | 0.063
24 | PCDHA13 | protocadherin alpha 13 | 162857 | 8 | 6 | 8 | 0 | 3 | 1 | 2 | 1 | 1 | 0 | 0.000098 | 0.073
25 | C4BPA | complement component 4 binding protein, alpha | 126397 | 5 | 5 | 5 | 1 | 2 | 2 | 0 | 0 | 1 | 0 | 0.00011 | 0.078
26 | CSMD3 | CUB and Sushi multiple domains 3 | 787754 | 11 | 9 | 11 | 6 | 2 | 4 | 2 | 2 | 1 | 0 | 0.00014 | 0.096
27 | KCNS2 | potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 | 80231 | 5 | 5 | 5 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0.00016 | 0.11
28 | CASP14 | caspase 14, apoptosis-related cysteine peptidase | 51900 | 5 | 4 | 4 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0.00018 | 0.12
29 | RBM10 | RNA binding motif protein 10 | 160754 | 5 | 5 | 4 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0.00021 | 0.13
30 | SLITRK1 | SLIT and NTRK-like family, member 1 | 134633 | 6 | 5 | 6 | 0 | 2 | 1 | 2 | 0 | 1 | 0 | 0.00029 | 0.17
31 | OSBPL6 | oxysterol binding protein-like 6 | 208053 | 5 | 5 | 5 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0.0003 | 0.17
32 | DKK4 | dickkopf homolog 4 (Xenopus laevis) | 46838 | 3 | 3 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0.00032 | 0.18
33 | LIFR | leukemia inhibitory factor receptor alpha | 228178 | 5 | 5 | 5 | 2 | 0 | 2 | 1 | 1 | 1 | 0 | 0.00036 | 0.2
34 | SAMD9L | sterile alpha motif domain containing 9-like | 327283 | 9 | 6 | 9 | 1 | 1 | 6 | 1 | 0 | 1 | 0 | 0.00042 | 0.22
35 | FAT4 | FAT tumor suppressor homolog 4 (Drosophila) | 968552 | 17 | 10 | 17 | 5 | 5 | 8 | 3 | 0 | 1 | 0 | 0.00043 | 0.22

COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 10. Number of genes displayed: 10

rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 38 | 52 | 37 | 3588 | 363199 | 1.6e-13 | 7.2e-10
2 | TP53 | tumor protein p53 | 45 | 824 | 45 | 56856 | 17987 | 1.6e-12 | 2.4e-09
3 | APC | adenomatous polyposis coli | 66 | 839 | 50 | 57891 | 1048 | 1.6e-12 | 2.4e-09
4 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 5 | 33 | 5 | 2277 | 5755 | 3.1e-11 | 3.5e-08
5 | FBXW7 | F-box and WD repeat domain containing 7 | 12 | 91 | 6 | 6279 | 329 | 4.5e-11 | 4.1e-08
6 | SMAD4 | SMAD family member 4 | 8 | 159 | 6 | 10971 | 39 | 1.2e-09 | 9.2e-07
7 | KRTAP5-5 | keratin associated protein 5-5 | 2 | 1 | 2 | 69 | 2 | 1.9e-07 | 0.00012
8 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 4 | 42 | 3 | 2898 | 6 | 3e-06 | 0.0017
9 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 7 | 220 | 4 | 15180 | 1382 | 0.000013 | 0.0067
10 | LRP1B | low density lipoprotein-related protein 1B (deleted in tumors) | 20 | 18 | 2 | 1242 | 2 | 0.000063 | 0.028

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Clustered Mutations

Table 5. Get Full Table Genes with Clustered Mutations

num | gene | desc | n | mindist | nmuts0 | nmuts3 | nmuts12 | npairs0 | npairs3 | npairs12
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
3873 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 38 | 0 | 278 | 416 | 445 | 278 | 416 | 445
7548 | TP53 | tumor protein p53 | 45 | 0 | 37 | 61 | 105 | 37 | 61 | 105
392 | APC | adenomatous polyposis coli | 66 | 0 | 11 | 21 | 47 | 11 | 21 | 47
2614 | FBXW7 | F-box and WD repeat domain containing 7 | 12 | 0 | 6 | 6 | 6 | 6 | 6 | 6
4876 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 5 | 0 | 6 | 6 | 6 | 6 | 6 | 6
6842 | SMAD4 | SMAD family member 4 | 8 | 0 | 4 | 4 | 6 | 4 | 4 | 6
2361 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 4 | 0 | 3 | 3 | 3 | 3 | 3 | 3
3783 | KIAA1804 |  | 11 | 0 | 2 | 6 | 7 | 2 | 6 | 7
3466 | IL1RAPL2 | interleukin 1 receptor accessory protein-like 2 | 5 | 0 | 1 | 3 | 3 | 1 | 3 | 3
2083 | DNAH5 | dynein, axonemal, heavy chain 5 | 19 | 0 | 1 | 2 | 2 | 1 | 2 | 2

Note:

n - number of mutations in this gene in the individual set.

mindist - distance (in aa) between closest pair of mutations in this gene

npairs3 - how many pairs of mutations are within 3 aa of each other.

npairs12 - how many pairs of mutations are within 12 aa of each other.

Geneset Analyses

Table 6. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 111. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | WNT_SIGNALING | Wnt signaling genes | APC, ARHA, AXIN1, C2orf31, CCND1, CCND2, CCND3, CSNK1E, CSNK1E, LOC400927, CTNNB1, DIPA, DVL1, DVL2, DVL3, FBXW2, FOSL1, FRAT1, FZD1, FZD10, FZD2, FZD3, FZD5, FZD6, FZD7, FZD8, FZD9, GSK3B, JUN, LDLR, MAPK10, MAPK9, MYC, PAFAH1B1, PLAU, PPP2R5C, PPP2R5E, PRKCA, PRKCB1, PRKCD, PRKCE, PRKCG, PRKCH, PRKCI, PRKCM, PRKCQ, PRKCZ, PRKD1, RAC1, RHOA, SFRP4, TCF7, WNT1, WNT10A, WNT10B, WNT11, WNT16, WNT2, WNT2B, WNT3, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B | 57 | APC(66), AXIN1(1), CTNNB1(4), DVL2(1), DVL3(2), FBXW2(1), FZD1(1), FZD10(2), FZD3(3), FZD6(3), GSK3B(1), LDLR(1), MAPK10(4), MAPK9(2), PLAU(1), PPP2R5C(1), PRKCA(2), PRKCE(2), PRKCG(2), PRKCH(1), PRKCQ(1), PRKD1(5), RHOA(1), SFRP4(1), TCF7(3), WNT10B(1), WNT2(1), WNT2B(2), WNT6(1) | 5514820 | 117 | 58 | 107 | 13 | 15 | 27 | 8 | 0 | 49 | 18 | <1.00e-15 | <8.25e-14
2 | TELPATHWAY | Telomerase is a ribonucleotide protein that adds telomeric repeats to the 3' ends of chromosomes. | AKT1, BCL2, EGFR, G22P1, HSPCA, IGF1R, KRAS2, MYC, POLR2A, PPP2CA, PRKCA, RB1, TEP1, TERF1, TERT, TNKS, TP53, XRCC5 | 15 | EGFR(1), IGF1R(1), PRKCA(2), RB1(3), TERF1(1), TP53(45), XRCC5(2) | 2767314 | 55 | 48 | 40 | 6 | 22 | 9 | 9 | 2 | 13 | 0 | <1.00e-15 | <8.25e-14
3 | HSA04810_REGULATION_OF_ACTIN_CYTOSKELETON | Genes involved in regulation of actin cytoskeleton | ABI2, ACTN1, ACTN2, ACTN3, ACTN4, APC, APC2, ARAF, ARHGEF1, ARHGEF12, ARHGEF4, ARHGEF6, ARHGEF7, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5, ARPC5L, BAIAP2, BCAR1, BDKRB1, BDKRB2, BRAF, C3orf10, CD14, CDC42, CFL1, CFL2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CRK, CRKL, CSK, CYFIP1, CYFIP2, DIAPH1, DIAPH2, DIAPH3, DOCK1, EGF, EGFR, EZR, F2, F2R, FGD1, FGD3, FGF1, FGF10, FGF11, FGF12, FGF13, FGF14, FGF16, FGF17, FGF18, FGF19, FGF2, FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FN1, GIT1, GNA12, GNA13, GNG12, GRLF1, GSN, HRAS, INS, IQGAP1, IQGAP2, IQGAP3, ITGA1, ITGA10, ITGA11, ITGA2, ITGA2B, ITGA3, ITGA4, ITGA5, ITGA6, ITGA7, ITGA8, ITGA9, ITGAD, ITGAE, ITGAL, ITGAM, ITGAV, ITGAX, ITGB1, ITGB2, ITGB3, ITGB4, ITGB5, ITGB6, ITGB7, ITGB8, KRAS, LIMK1, LIMK2, LOC200025, LOC645126, LOC653888, MAP2K1, MAP2K2, MAPK1, MAPK3, MLCK, MOS, MRAS, MRCL3, MRLC2, MSN, MYH10, MYH14, MYH9, MYL2, MYL5, MYL7, MYL8P, MYL9, MYLC2PL, MYLK, MYLK2, MYLPF, NCKAP1, NCKAP1L, NRAS, PAK1, PAK2, PAK3, PAK4, PAK6, PAK7, PDGFA, PDGFB, PDGFRA, PDGFRB, PFN1, PFN2, PFN3, PFN4, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5, PIP4K2A, PIP4K2B, PIP4K2C, PIP5K1A, PIP5K1B, PIP5K1C, PIP5K3, PPP1CA, PPP1CB, PPP1CC, PPP1R12A, PPP1R12B, PTK2, PXN, RAC1, RAC2, RAC3, RAF1, RDX, RHOA, ROCK1, ROCK2, RRAS, RRAS2, SCIN, SLC9A1, SOS1, SOS2, SSH1, SSH2, SSH3, TIAM1, TIAM2, TMSB4X, TMSB4Y, TMSL3, VAV1, VAV2, VAV3, VCL, WAS, WASF1, WASF2, WASL | 203 | ABI2(1), ACTN1(2), ACTN2(1), ACTN3(1), ACTN4(1), APC(66), ARHGEF1(1), ARHGEF12(2), ARHGEF4(1), ARHGEF6(3), ARPC2(1), ARPC5L(1), BAIAP2(1), BDKRB2(1), BRAF(2), CDC42(1), CHRM2(3), CHRM4(1), CHRM5(1), CSK(2), CYFIP1(1), CYFIP2(1), DIAPH2(3), DIAPH3(2), DOCK1(2), EGFR(1), F2(1), FGD1(2), FGD3(1), FGF11(1), FGF12(1), FGF13(1), FGF19(1), FGF20(1), FGF5(2), FGFR1(1), FGFR2(5), FN1(4), GIT1(1), GRLF1(5), IQGAP1(3), IQGAP2(3), ITGA10(4), ITGA11(2), ITGA2(1), ITGA2B(2), ITGA4(5), ITGA6(1), ITGA8(3), ITGA9(2), ITGAD(1), ITGAE(2), ITGAL(3), ITGAM(3), ITGAV(4), ITGAX(2), ITGB2(1), ITGB3(2), ITGB4(1), ITGB5(1), ITGB8(1), KRAS(38), LIMK1(1), LIMK2(1), MAP2K1(1), MAP2K2(1), MAPK3(1), MOS(1), MSN(3), MYH10(2), MYH14(3), MYH9(3), MYL9(2), MYLK(3), MYLK2(1), NCKAP1(1), NCKAP1L(4), NRAS(5), PAK1(1), PAK2(1), PAK3(2), PAK7(3), PDGFRA(4), PDGFRB(1), PIK3CA(7), PIK3CD(1), PIK3CG(2), PIK3R1(5), PIK3R3(4), PIP5K1B(1), PIP5K1C(1), PPP1CB(1), PPP1CC(1), PPP1R12A(1), PPP1R12B(4), RAF1(2), RDX(1), RHOA(1), ROCK1(7), ROCK2(4), RRAS2(1), SCIN(1), SLC9A1(2), SOS1(2), SOS2(2), SSH1(2), SSH3(1), TIAM1(5), TIAM2(2), VAV1(2), VAV2(2), VAV3(2), VCL(1), WASF1(2), WASL(2) | 26346557 | 332 | 66 | 291 | 70 | 74 | 124 | 38 | 4 | 72 | 20 | 1.11e-15 | 8.25e-14
4 | ALKPATHWAY | Activin receptor-like kinase 3 (ALK3) is required during gestation for cardiac muscle development. | ACVR1, APC, ATF2, AXIN1, BMP10, BMP2, BMP4, BMP5, BMP7, BMPR1A, BMPR2, CHRD, CTNNB1, DVL1, FZD1, GATA4, GSK3B, MADH1, MADH4, MADH5, MADH6, MAP3K7, MEF2C, MYL2, NKX2-5, NOG, NPPA, NPPB, RFC1, TCF1, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, TGFBR3, WNT1 | 31 | ACVR1(1), APC(66), ATF2(1), AXIN1(1), BMP10(1), BMP2(1), BMP4(1), BMP5(1), BMP7(1), BMPR2(3), CTNNB1(4), FZD1(1), GSK3B(1), MAP3K7(2), MEF2C(2), NPPB(1), RFC1(4), TGFB2(4), TGFBR1(3), TGFBR3(3) | 3414527 | 102 | 59 | 92 | 3 | 13 | 19 | 9 | 0 | 43 | 18 | 1.11e-15 | 8.25e-14
5 | HSA04664_FC_EPSILON_RI_SIGNALING_PATHWAY | Genes involved in Fc epsilon RI signaling pathway | AKT1, AKT2, AKT3, BTK, CSF2, FCER1A, FCER1G, FYN, GAB2, GRB2, HRAS, IL13, IL3, IL4, IL5, INPP5D, KRAS, LAT, LCP2, LYN, MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K6, MAP2K7, MAPK1, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPK8, MAPK9, MS4A2, NRAS, PDK1, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5, PLA2G10, PLA2G12A, PLA2G12B, PLA2G1B, PLA2G2A, PLA2G2D, PLA2G2E, PLA2G2F, PLA2G3, PLA2G4A, PLA2G5, PLA2G6, PLCG1, PLCG2, PRKCA, PRKCB1, PRKCD, PRKCE, RAC1, RAC2, RAC3, RAF1, SOS1, SOS2, SYK, TNF, VAV1, VAV2, VAV3 | 74 | AKT2(1), AKT3(1), BTK(1), FCER1A(1), FYN(1), GRB2(1), INPP5D(2), KRAS(38), LAT(1), LCP2(1), MAP2K1(1), MAP2K2(1), MAP2K3(4), MAP2K4(2), MAP2K6(1), MAPK10(4), MAPK13(1), MAPK3(1), MAPK8(5), MAPK9(2), MS4A2(2), NRAS(5), PDK1(2), PIK3CA(7), PIK3CD(1), PIK3CG(2), PIK3R1(5), PIK3R3(4), PLA2G4A(3), PLA2G6(2), PLCG2(4), PRKCA(2), PRKCE(2), RAF1(2), SOS1(2), SOS2(2), SYK(3), VAV1(2), VAV2(2), VAV3(2) | 6895491 | 126 | 49 | 95 | 19 | 28 | 63 | 16 | 2 | 15 | 2 | 1.11e-15 | 8.25e-14
6 | ST_WNT_BETA_CATENIN_PATHWAY | Beta-catenin is degraded in the absence of Wnt signaling; when extracellular Wnt binds Frizzled receptors, beta-catenin accumulates in the nucleus and may promote cell survival. | AKT1, AKT2, AKT3, ANKRD6, APC, AXIN1, AXIN2, C22orf2, CER1, CSNK1A1, CTNNB1, DACT1, DKK1, DKK2, DKK3, DKK4, DVL1, FRAT1, FSTL1, GSK3A, GSK3B, IDAX, LAMR1, LRP1, MVP, NKD1, NKD2, PIN1, PSEN1, PTPRA, SENP2, SFRP1, TSHB, WIF1 | 29 | AKT2(1), AKT3(1), APC(66), AXIN1(1), AXIN2(2), CTNNB1(4), DACT1(1), DKK1(2), DKK2(1), DKK4(3), FSTL1(1), GSK3B(1), LRP1(3), SENP2(1), SFRP1(1), TSHB(1) | 3759900 | 90 | 59 | 80 | 4 | 8 | 14 | 11 | 0 | 39 | 18 | 1.33e-15 | 8.25e-14
7 | HSA04370_VEGF_SIGNALING_PATHWAY | Genes involved in VEGF signaling pathway | AKT1, AKT2, AKT3, BAD, CASP9, CDC42, CHP, HRAS, KDR, KRAS, MAP2K1, MAP2K2, MAPK1, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPKAPK2, MAPKAPK3, NFAT5, NFATC1, NFATC2, NFATC3, NFATC4, NOS3, NRAS, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5, PLA2G10, PLA2G12A, PLA2G12B, PLA2G1B, PLA2G2A, PLA2G2D, PLA2G2E, PLA2G2F, PLA2G3, PLA2G4A, PLA2G5, PLA2G6, PLCG1, PLCG2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PRKCA, PRKCB1, PRKCG, PTGS2, PTK2, PXN, RAC1, RAC2, RAC3, RAF1, SH2D2A, SHC2, SPHK1, SPHK2, SRC, VEGFA | 69 | AKT2(1), AKT3(1), CDC42(1), KDR(2), KRAS(38), MAP2K1(1), MAP2K2(1), MAPK13(1), MAPK3(1), NFATC1(1), NFATC2(2), NFATC3(1), NFATC4(1), NRAS(5), PIK3CA(7), PIK3CD(1), PIK3CG(2), PIK3R1(5), PIK3R3(4), PLA2G4A(3), PLA2G6(2), PLCG2(4), PPP3CA(2), PPP3CB(1), PPP3CC(1), PRKCA(2), PRKCG(2), PTGS2(1), RAF1(2), SH2D2A(1), SHC2(1), SPHK1(1) | 6915053 | 99 | 50 | 68 | 19 | 27 | 50 | 10 | 0 | 10 | 2 | 1.44e-15 | 8.25e-14
8 | TIDPATHWAY | On ligand binding, interferon gamma receptors stimulate JAK2 kinase to phosphorylate STAT transcription factors, which promote expression of interferon responsive genes. | DNAJA3, HSPA1A, IFNG, IFNGR1, IFNGR2, IKBKB, JAK2, LIN7A, NFKB1, NFKBIA, RB1, RELA, TIP-1, TNF, TNFRSF1A, TNFRSF1B, TP53, USH1C, WT1 | 17 | DNAJA3(1), IFNGR1(1), IFNGR2(1), IKBKB(2), JAK2(3), NFKB1(3), RB1(3), TP53(45), USH1C(3), WT1(2) | 1809425 | 64 | 48 | 49 | 6 | 25 | 14 | 7 | 2 | 15 | 1 | 1.55e-15 | 8.25e-14
9 | TGFBPATHWAY | The TGF-beta receptor responds to ligand binding by activating the SMAD family of transcriptional regulations, commonly blocking cell growth. | APC, CDH1, CREBBP, EP300, MADH2, MADH3, MADH4, MADH7, MADHIP, MAP2K1, MAP3K7, MAP3K7IP1, MAPK3, SKIL, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2 | 13 | APC(66), CDH1(1), CREBBP(4), EP300(2), MAP2K1(1), MAP3K7(2), MAPK3(1), SKIL(1), TGFB2(4), TGFBR1(3) | 2554178 | 85 | 57 | 75 | 4 | 5 | 10 | 8 | 0 | 44 | 18 | 1.78e-15 | 8.25e-14
10 | ST_FAS_SIGNALING_PATHWAY | The Fas receptor induces apoptosis and NF-kB activation when bound to Fas ligand. | ADPRT, ALG2, BAK1, BAX, BFAR, BIRC4, BTK, CAD, CASP10, CASP3, CASP8, CASP8AP2, CD7, CDK2AP1, CSNK1A1, DAXX, DEDD, DEDD2, DFFA, DIABLO, EGFR, EPHB2, FADD, FAF1, FAIM2, FREQ, HRB, HSPB1, IL1A, IL8, MAP2K4, MAP2K7, MAP3K1, MAP3K5, MAPK1, MAPK10, MAPK8, MAPK8IP1, MAPK8IP2, MAPK8IP3, MAPK9, MCP, MET, NFAT5, NFKB1, NFKB2, NFKBIA, NFKBIB, NFKBIE, NFKBIL1, NFKBIL2, NR0B2, PFN1, PFN2, PTPN13, RALBP1, RIPK1, ROCK1, SMPD1, TNFRSF6, TNFRSF6B, TP53, TPX2, TRAF2, TUFM, VIL2 | 59 | BTK(1), CAD(1), CASP3(1), CASP8AP2(6), DAXX(1), DEDD(1), DFFA(1), EGFR(1), EPHB2(1), IL8(1), MAP2K4(2), MAP3K1(2), MAP3K5(1), MAPK10(4), MAPK8(5), MAPK8IP3(1), MAPK9(2), MET(1), NFKB1(3), NFKB2(2), PTPN13(9), RALBP1(2), ROCK1(7), TP53(45), TPX2(1) | 6826271 | 102 | 50 | 87 | 17 | 34 | 28 | 17 | 3 | 20 | 0 | 2.00e-15 | 8.25e-14

Table 7. Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | C21_STEROID_HORMONE_METABOLISM |  | AKR1C4, AKR1D1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP21A2, HSD11B1, HSD11B2, HSD3B1, HSD3B2 | 11 | AKR1C4(1), AKR1D1(1), CYP11A1(2), CYP11B1(4), CYP21A2(1), HSD3B1(1), HSD3B2(1) | 837086 | 11 | 10 | 11 | 2 | 3 | 5 | 1 | 0 | 2 | 0 | 0.0014 | 0.3
2 | HSA00140_C21_STEROID_HORMONE_METABOLISM | Genes involved in C21-steroid hormone metabolism | AKR1C4, AKR1D1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP21A2, HSD11B1, HSD11B2, HSD3B1, HSD3B2 | 11 | AKR1C4(1), AKR1D1(1), CYP11A1(2), CYP11B1(4), CYP21A2(1), HSD3B1(1), HSD3B2(1) | 837086 | 11 | 10 | 11 | 2 | 3 | 5 | 1 | 0 | 2 | 0 | 0.0014 | 0.3
3 | ERBB4PATHWAY | ErbB4 (aka HER4) is a receptor tyrosine kinase that binds neuregulins as well as members of the EGF family, which also target EGF receptors. | ADAM17, ERBB4, NRG2, NRG3, PRKCA, PRKCB1, PSEN1 | 6 | ADAM17(1), ERBB4(5), NRG2(2), NRG3(4), PRKCA(2) | 908762 | 14 | 9 | 14 | 1 | 4 | 5 | 1 | 1 | 3 | 0 | 0.0014 | 0.3
4 | HSA00240_PYRIMIDINE_METABOLISM | Genes involved in pyrimidine metabolism | AICDA, AK3, CAD, CANT1, CDA, CMPK, CTPS, CTPS2, DCK, DCTD, DHODH, DPYD, DPYS, DTYMK, DUT, ECGF1, ENTPD1, ENTPD3, ENTPD4, ENTPD5, ENTPD6, ENTPD8, ITPA, NME1, NME2, NME4, NME6, NME7, NP, NT5C, NT5C1A, NT5C1B, NT5C2, NT5C3, NT5E, NT5M, NUDT2, PNPT1, POLA1, POLA2, POLD1, POLD2, POLD3, POLD4, POLE, POLE2, POLE3, POLE4, POLR1A, POLR1B, POLR1C, POLR1D, POLR2A, POLR2B, POLR2C, POLR2D, POLR2E, POLR2F, POLR2G, POLR2H, POLR2I, POLR2J, POLR2K, POLR2L, POLR3A, POLR3B, POLR3G, POLR3GL, POLR3H, POLR3K, PRIM1, PRIM2, RFC5, RRM1, RRM2, RRM2B, TK1, TK2, TXNRD1, TXNRD2, TYMS, UCK1, UCK2, UMPS, UPB1, UPP1, UPP2, UPRT, ZNRD1 | 86 | AICDA(1), CAD(1), CTPS(1), DCK(1), DHODH(1), DPYD(6), DPYS(1), DTYMK(1), ENTPD5(1), ENTPD6(1), NME6(1), NME7(2), NT5C1B(1), NT5C2(1), NT5E(1), PNPT1(5), POLA1(3), POLE(4), POLE2(1), POLR1A(3), POLR1B(2), POLR2B(3), POLR2K(1), POLR3A(4), POLR3B(5), POLR3K(1), PRIM2(3), RFC5(1), RRM1(1), TK2(1), TXNRD1(1), TXNRD2(1), TYMS(1), UMPS(1), UPB1(2), UPP2(1), UPRT(1) | 7933506 | 67 | 28 | 65 | 15 | 18 | 26 | 10 | 0 | 13 | 0 | 0.0046 | 0.65
5 | CREMPATHWAY | The transcription factor CREM activates a post-meiotic transcriptional cascade culminating in spermatogenesis. | ADCY1, CREM, FHL5, FSHB, FSHR, GNAS, XPO1 | 7 | ADCY1(4), FHL5(3), FSHB(1), FSHR(1), XPO1(1) | 917313 | 10 | 9 | 10 | 4 | 4 | 1 | 3 | 1 | 1 | 0 | 0.0053 | 0.65
6 | GSPATHWAY | Activated G-protein coupled receptors stimulate cAMP production and thus activate protein kinase A, involved in a number of signal transduction pathways. | ADCY1, GNAS, GNB1, GNGT1, PRKACA, PRKAR1A | 6 | ADCY1(4), GNGT1(1), PRKACA(1), PRKAR1A(4) | 607553 | 10 | 8 | 10 | 1 | 3 | 4 | 1 | 0 | 2 | 0 | 0.0071 | 0.7
7 | PAR1PATHWAY | Activated extracellular thrombin cleaves and activates the G-protein coupled receptors PAR1 and PAR4, which activate platelets. | ADCY1, ARHA, ARHGEF1, F2, F2R, F2RL3, GNA12, GNA13, GNAI1, GNAQ, GNB1, GNGT1, MAP3K7, PIK3CA, PIK3R1, PLCB1, PPP1R12B, PRKCA, PRKCB1, PTK2B, ROCK1 | 18 | ADCY1(4), ARHGEF1(1), F2(1), GNAI1(1), GNAQ(1), GNGT1(1), MAP3K7(2), PIK3R1(5), PPP1R12B(4), PRKCA(2), ROCK1(7) | 2322908 | 29 | 13 | 29 | 7 | 8 | 7 | 5 | 0 | 7 | 2 | 0.008 | 0.7
8 | NEUROTRANSMITTERSPATHWAY | Biosynthesis of neurotransmitters | DBH, GAD1, HDC, PNMT, TH, TPH1 | 6 | DBH(1), GAD1(2), HDC(5), TPH1(2) | 572489 | 10 | 7 | 10 | 2 | 3 | 5 | 1 | 0 | 1 | 0 | 0.01 | 0.77
9 | HSA00150_ANDROGEN_AND_ESTROGEN_METABOLISM | Genes involved in androgen and estrogen metabolism | AKR1C4, AKR1D1, ARSD, ARSE, CARM1, CYP11B1, CYP11B2, CYP19A1, HEMK1, HSD11B1, HSD11B2, HSD17B1, HSD17B12, HSD17B2, HSD17B3, HSD17B7, HSD17B8, HSD3B1, HSD3B2, LCMT1, LCMT2, METTL2B, METTL6, PRMT2, PRMT3, PRMT5, PRMT6, PRMT7, PRMT8, SRD5A1, SRD5A2, STS, SULT1E1, SULT2A1, SULT2B1, UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT2A1, UGT2A3, UGT2B10, UGT2B11, UGT2B15, UGT2B17, UGT2B28, UGT2B4, UGT2B7, WBSCR22 | 53 | AKR1C4(1), AKR1D1(1), CYP11B1(4), CYP19A1(3), HSD17B2(1), HSD17B3(1), HSD3B1(1), HSD3B2(1), LCMT1(2), METTL2B(1), METTL6(3), PRMT3(1), PRMT7(1), PRMT8(2), SRD5A2(1), STS(1), SULT1E1(1), SULT2A1(1), UGT1A4(1), UGT1A6(1), UGT1A8(1), UGT1A9(1), UGT2A3(2), UGT2B11(2), UGT2B17(3), UGT2B28(1), UGT2B4(1), UGT2B7(2) | 4462401 | 42 | 18 | 42 | 9 | 9 | 19 | 6 | 1 | 7 | 0 | 0.012 | 0.77
10 | HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM | Genes involved in D-arginine and D-ornithine metabolism | DAO | 1 | DAO(4) | 73821 | 4 | 3 | 4 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0.012 | 0.77

Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2013 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle